NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company's proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company said NV-387 is a broad-spectrum antiviral designed to target host-cell features required by viruses and is the only orally administered Ebola treatment candidate currently under consideration for clinical testing, to its knowledge.
NanoViricides said the next steps include obtaining approvals from the DRC National Ethics Committee and regulatory agency ACOREP before initiating the study. The company noted that NV-387 Oral Gummies have already received authorization in the DRC for a Phase II mpox trial and are ready for shipment. Management believes the oral formulation could offer significant advantages in resource-limited outbreak settings, where intravenous treatments can be difficult to deploy and scale. For more details, visit https://nnw.fm/1ewVT.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug that the company plans to develop as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company's advanced drug candidate NV-HHV-1 targets Shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
This approval is significant because it represents a potential shift in Ebola treatment from intravenous to oral administration, which could greatly improve accessibility in remote outbreak zones. The DRC has experienced multiple Ebola outbreaks, and the ability to deploy an oral treatment like NV-387 Oral Gummies could enhance outbreak response efforts. If successful, this trial could pave the way for broader use of oral antivirals in viral hemorrhagic fevers, addressing a critical gap in pandemic preparedness.
Investors can find the latest news and updates relating to NNVC in the company's newsroom at https://nnw.fm/NNVC.
